A multicenter, cross‐sectional analysis to assess the safety and usage pattern of brivaracetam in the management of partial‐onset seizure with BAEs—BREEZE study: A post‐hoc analysis

Documenti analoghi

• Real‐world retention of newer ASMs , including lacosamide and brivaracetam as first or second therapies in adult‐onset epilepsy
  di: André Idegård, et al.
  Pubblicazione: (2025)
• A cross‐national cost‐effectiveness analysis of brivaracetam focusing on psychiatric and behavioral adverse effects
  di: Yasushi Maruyama, et al.
  Pubblicazione: (2025)
• Long‐term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal‐onset seizures or generalized tonic–clonic seizures
  di: Robert Flamini, et al.
  Pubblicazione: (2025)
• Combined value of interictal markers and stimulated seizures to estimate the seizure onset zone in stereoelectroencephalography
  di: Lauri Rekola, et al.
  Pubblicazione: (2024)
• Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial
  di: David G. Vossler, et al.
  Pubblicazione: (2024)